m6A-modified miR-143-3p inhibits epithelial mesenchymal transition in bronchial epithelial cells and extracellular matrix production in lung fibroblasts by targeting Smad3
Pulmonary Pharmacology & Therapeutics · 2023-12 · 83 · 102251
DOI: 10.1016/j.pupt.2023.102251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Pharmacology & Therapeutics, 2023-12. Verfasst von Jing Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Asthma, Xi'an Children's Hospital, Xi'an, Shaanxi, 710003, China. Hauptthemen laut MEDLINE: Asthma, MicroRNAs. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Airway epithelial cells epithelial mesenchymal transition (EMT) and lung fibroblasts extracellular matrix (ECM) production are the key steps in airway remodeling. Our previous study demonstrated that miR-143-3p has the ability to impede airway smooth muscle cell proliferation and ECM deposition. However, the function of miR-143-3p in airway epithelial cells and lung fibroblasts remains unclear. METHODS: Cell viability was determined using MTT method, while cell migration was evaluated through scratch assay. EMT and ECM proteins were detected by western blot, RT-qPCR, and ELISA. To determine the level of miR-143-3p m6A methylation, we employed the meRIP-qPCR assay. Additionally, the binding of miR-143-3p with Smad3 were projected by bioinformatics and validated by dual luciferase reporter assays. RESULTS: It was discovered that the expression of miR-143-3p were lower in both asthma patients and TGF-β1-treated human bronchial epithelial 16HBE cells and human lung fibroblast HPF cells. Upregulation of miR-143-3p restrained 16HBE cell migration, and decreased EMT mesenchymal markers and increased epithelial markers. And upregulation of miR-143-3p impaired cell viability and ECM protein production in HPF cells. Mechanistically, interfering with METTL3 resulted in decreased m6A modification of miR-143-3p and led to lower levels of miR-143-3p. Moreover, miR-143-3p were verified to directly target and downregulate Smad3. Upregulation of Smad3 attenuated the effects of miR-143-3p on cell EMT and ECM production. CONCLUSION: MiR-143-3p inhibits airway epithelial cell EMT as well as lung fibroblast ECM production by downregulating Smad3. Therefore, miR-143-3p may be a promising target to reduce airway remodeling in asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Asthma, Xi'an Children's Hospital, Xi'an, Shaanxi, 710003, China.
- Department of Emergency, Xi'an Children's Hospital, Xi'an, Shaanxi, 710003, China.
- Department of General Surgery, 2nd Affiliated Hospital, Medical School of Xi'an Jiaotong University, Xi'an, Shaanxi, 710004, China.
- Department of Internal Medicine, Xi'an Children's Hospital, Xi'an, Shaanxi, 710003, China.
- Department of Internal Medicine, Xi'an Children's Hospital, Xi'an, Shaanxi, 710003, China. Electronic address: weichengc3@126.com.
Zitieren
APA
Wang, J., Jian, Q., Yan, K., Yang, J., Yan, L., & Cheng, W. (2023). m6A-modified miR-143-3p inhibits epithelial mesenchymal transition in bronchial epithelial cells and extracellular matrix production in lung fibroblasts by targeting Smad3. Pulmonary Pharmacology & Therapeutics, 83, 102251. https://doi.org/10.1016/j.pupt.2023.102251
Vancouver
Wang J, Jian Q, Yan K, Yang J, Yan L, Cheng W. m6A-modified miR-143-3p inhibits epithelial mesenchymal transition in bronchial epithelial cells and extracellular matrix production in lung fibroblasts by targeting Smad3. Pulmonary Pharmacology & Therapeutics. 2023;83:102251. doi:10.1016/j.pupt.2023.102251
BibTeX
@article{Wang2023,
author = {Wang, Jing and Jian, Qiang and Yan, Kun and Yang, Jiao and Yan, Liping and Cheng, Wei},
title = {m6A-modified miR-143-3p inhibits epithelial mesenchymal transition in bronchial epithelial cells and extracellular matrix production in lung fibroblasts by targeting Smad3},
journal = {Pulmonary Pharmacology & Therapeutics},
year = {2023},
volume = {83},
pages = {102251},
doi = {10.1016/j.pupt.2023.102251}
}
EUVIMED